Lupus myocarditis: a single center experience and a comparative analysis of observational cohort studies

Abstract

Background Lupus myocarditis (LM) is reported in 3-9% of patients with systemic lupus erythematosus (SLE) but limited evidence exists regarding optimal treatment and prognosis. This study aims to describe LM in a defined lupus cohort as compared with the existing literature. Patients and methods Patients with LM were identified from the University of Toronto Lupus Clinic database. Diagnosis was based on clinical manifestations and electrocardiographic, imaging, and biochemical criteria. Demographic, clinical, diagnostic and therapeutic variables and outcomes were collected in a standardized data retrieval form. A literature review was performed to identify cohort studies reporting on LM treatment and outcome. A comparative analysis was conducted between our patients and the combined cohort of the existing studies. Results Thirty patients were diagnosed with LM (prevalence 1.6%) and compared with a cumulative cohort of 117 patients from five distinct studies. No significant differences were found regarding the age at diagnosis (32.6 ± 13.4 years) and SLE duration (2.5 years median). Concomitant lupus activity from other organ systems was observed in 97% of the patients. Chest pain was more frequently reported in our cohort whereas dyspnea was more prominent in the other studies. Diagnostic criteria were similar across studies. Therapeutic approach was comparable and consisted of glucocorticosteroids (96.6%) and immunosuppressives (70%). Mortality was approximately 20% whereas another 20% of the patients achieved partial and 60% complete recovery. Conclusions LM usually occurs early in the disease course and in the context of generalized lupus activity. Despite aggressive therapy, approximately 40% of the patients died or had residual heart damage.

Lupus myocarditis in an octogenarian patient—a case report

“…Previous reports showed that prevalence of lupus myocarditis is 5–10% of patients [ 3 , 4 ], and mortality may be as high as 10.3% according to a large case series from Paris [ 6 ]. Although other studies report that concomitant lupus activity in various organ occurs in 97% of the patients with lupus myocarditis [ 7 ], our report provides a rare evidence that lupus myocarditis may be a sole manifestation. Clearly, given the rarity of myocardial involvement, diagnosis is elusive.…”

Therapeutic strategies for virus-negative myocarditis: a comprehensive review

“…The importance of targeting inflammatory mediators of myocardial damage to improve patient's outcome was also emphasized in three monocentric cohorts of patients who developed myocarditis in the context of CTDs. In this studies MMF was the first-line immunosuppressive therapy in 4 out of 12 patients with anti-synthetase syndrome [39], in 6 out of 30 patients with SLE [41], and in 3 patients with myocarditis in the context of anti-Ku positive SSc [18]. However, follow-up data were not reported in these studies and firm conclusions cannot be drawn.…”

“…Clinical and experimental evidence to support the use of B-cell depletion therapy with anti-CD20 monoclonal antibody rituximab (RTX) is poor. To date, only few observational studies and case reports described the efficacy of rituximab in VNM related to connective tissue diseases, mainly SLE [40,41,48].…”

Systemic Lupus Erythematosus Presenting as Myopericarditis with Acute Heart Failure: A Case Report and Literature Review

“…In the differential considerations of a patient with decompensated heart failure without typical cardiovascular risk factors, we find that, despite several cases being reported, heart failure as the initial manifestation of SLE remains exceedingly rare in the literature, as was observed in a large lupus cohort in Toronto over a period of more than 40 years. Acute lupus myocarditis as the presenting symptom of SLE remains a rare entity, with only 0.37% of patients presenting as such [23]. Due to lack of evidence-based consensus or a comprehensive review of the same, heart failure due to SLE continues to be an underrecognized phenomenon, thereby significantly delaying diagnosis and initiation of treatment.…”